Inhibition of proprotein convertases: Approaches to block squamous carcinoma development and progression

Molecular Carcinogenesis

Volumn 46, Issue 8, 2007, Pages 654-659

  López De Cicco, Ricardo ^a   Bassi, Daniel E ^a   Benavides, Fernando ^b   Conti, Claudio J ^b   Klein Szanto, Andres J P ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Furin; Pro protein convertases; Skin; Squamous cell carcinoma

Indexed keywords

DECANOYLARGINYLVALYLLYSYLARGINYL CHLOROMETHYL KETONE; FURIN; KETONE DERIVATIVE; MATRIX METALLOPROTEINASE 14; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN C;

BIOENGINEERING; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CARCINOMA CELL; CELL MEMBRANE; CONFERENCE PAPER; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; RNA INTERFERENCE; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; PROPROTEIN CONVERTASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 34547905029     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20331     Document Type: Conference Paper

References (61)

1. Fuller RS, Sterne RE, Thorner J. Enzymes required for yeast prohormone processing. Annu Rev Physiol 1988;50:345-362.
2. Julius D, Schekman R, Thorner J. Glycosylation and processing of prepro-alpha-factor through the yeast secretory pathway. Cell 1984;36:309-318.
3. Duguay SJ, Lai-Zhang J, Steiner DF. Mutational analysis of the insulin-like growth factor I prohormone processing site. J Biol Chem 1995;270:17566-17574.
4. Lehmann M, Andre F, Bellan C, Remacle-Bonnet M, Garrouste F, Parat F, Lissitsky JC, Marvaldi J, Pommier G. Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells. Endocrinology 1998;139:3763-3771.
5. Sato H, Kinoshita T, TakinoT, Nakayama K, Seiki M. Activation of a recombinant membrane type 1 -matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996;393:101-104.
6. Bergeron E, Basak A, Decroly E, Seidah NG. Processing of alpha4 integrin by the proprotein convertases: Histidine at position P6 regulates cleavage. Biochem J 2003;373:475-484.
7. Stawowy P, Graf K, Goetze S, Roser M, Chretien M, Seidah NG, Fleck E, Marcinkiewicz M. Coordinated regulation and colocalization of alphav integrin and its activating enzyme proprotein convertase PC5 in vivo. Histochem Cell Biol 2003;119:239-245.
8. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244-247.
9. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, Seidah NG. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 2001;158:305-316.
10. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 1992;267:16396-16402.
11. Seidah NG, Gaspar L, Mion P, Marcinkiewicz M, Mbikay M, Chretien M. cDNA sequence of two distinct pituitary proteins homologous to Kex2 and furin gene products: Tissue-specific mRNAs encoding candidates for pro-hormone processing proteinases. DNA Cell Biol 1990;9:789.
12. Seidah NG, Chretien M. Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Res 1999;848:45-62.
13. Seidah NG, Mowla SJ, Hamelin J, Mamarbachi AM, Benjannet S, Toure BB, Basak A, Munzer JS, Marcinkiewicz J, Zhong M, Barale JC, Lazure C, Murphy RA, Chretien M, Marcinkiewicz M. Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci U S A 1999;96:1321-1326.
14. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003;100:928-933.
15. Nakayama K. Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997;327:625-635.
16. Sakai J, Rawson RB, Espenshade PJ, Cheng D, Seegmiller AC, Goldstein JL, Brown MS. Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Mol Cell 1998;2:505-514.
17. Konoshita T, Gasc JM, Villard E, Takeda R, Seidah NG, Corvol P, Pinet F. Expression of PC2 and PC1/PC3 in human pheochromocytomas. Mol Cell Endocrinol 1994;99:307-314.
18. Breslin MB, Lindberg I, Benjannet S, Mathis JP, Lazure C, Seidah NG. Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin. J Biol Chem 1993;268:27084-27093.
19. Schalken JA, Roebroek AJ, Oomen PP, Wagenaar SS, Debruyne FM, Bloemers HP, Van de Ven WJ. fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest 1987;80:1545-1549.
20. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75:1509-1514.
21. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71:966-971.
22. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001;31:224-232.
23. Creemers JW, Roebroek AJ, Van de Ven WJ. Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3. Cloning and primary sequence of a 5 kb cDNA. FEBS Lett 1992;300:82-88.
24. Hubbard FC, Goodrow TL, Liu SC, Brilliant MH, Basset P, Mains RE, Klein-Szanto AJ. Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability. Cancer Res 1997;57:5226-5231.
25. Mahloogi H, Bassi DE, Klein-Szanto AJ. Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PA CE4. Carcinogenesis 2002;23:565-572.
26. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 2005;65:7310-7319.
27. Rovere C, Barbero P, Maoret JJ, Laburthe M, Kitabgi P. Pro-neurotensin/neuromedin N expression and processing in human colon cancer cell lines. Biochem Biophys Res Commun 1998;246:155-159.
28. Basak A, Schmidt C, Ismail AA, Seidah NG, Chretien M, Lazure C. Peptidyl substrates containing unnatural amino acid at the P′1 position are potent inhibitors of prohormone convertases. Int J Pept Protein Res 1995;46:228-237.
29. Lu W, Zhang W, Molloy SS, Thomas G, Ryan K, Chiang Y, Anderson S, Laskowski M Jr. Arg15-Lys17-Arg18 turkey ovomucoid third domain inhibits human furin. J Biol Chem 1993;268:14583-14585.
30. Dahlen JR, Jean F, Thomas G, Foster DC, Kisiel W. Inhibition of soluble recombinant furin by human proteinase inhibitor 8. J Biol Chem 1998;273:1851-1854.
31. Van Rompaey L, Ayoubi T, Van De Ven W, Marynen P. Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2-macroglobulin containing a furin recognition sequence in the bait region. Biochem J 1997;326:507-514.
32. Jean F, Stella K, Thomas L, Liu G, Xiang Y, Reason AJ, Thomas G. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: Application as an antipathogenic agent. Proc Natl Acad Sci USA 1998;95:7293-7298.
33. Benjannet S, Savaria D, Laslop A, Munzer JS, Chretien M, Marcinkiewicz M, Seidah NG. Alpha1-antitrypsin Portland inhibits processing of precursors mediated by proprotein convertases primarily within the constitutive secretory pathway. J Biol Chem 1997;272:26210-26218.
34. Perlmutter DH, Pierce JA. The alpha 1-antitrypsin gene and emphysema. Am J Physiol 1989;257:L147-L162.
35. Lewis JH, Iammarino RM, Spero JA, Hasiba U. Antithrombin Pittsburgh: An alpha1-antitrypsin variant causing hemorrhagic disease. Blood 1978;51:129-137.
36. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 309: 1983; 694-698.
37. Anderson ED, Thomas L, Hayflick JS, Thomas G. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem 1993;268:24887-24891.
38. Tsuji A, Hashimoto E, Ikoma T, Taniguchi T, Mori K, Nagahama M, Matsuda Y. Inactivation of proprotein convertase, PACE4, by alpha1-antitrypsin Portland (alpha1-PDX), a blocker of proteolytic activation of bone morphogenetic protein during embryogenesis: Evidence that PACE4 is able to form an SDS-stable acyl intermediate with alpha1-PD. J Biochem (Tokyo) 1999;126:591-603.
39. Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, Seidah NG. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 2001;276:30686-30693.
40. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, Seidah NG, Khatib AM. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003;111:1723-1732.
41. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 2001;98:10326-10331.
42. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, Klein-Szanto AJ. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002;8:1740-1746.
43. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ. Proprotein convertases: "Master switches" in the regulation of tumor growth and progression. Mol Carcinog 2005;44:151-161.
44. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: Novel targets in cancer therapy. Am J Pathol 2002;160:1921-1935.
45. Leduc R, Molloy SS, Thorne BA, Thomas G. Activation of human furin precursor processing endoprotease occurs by an intramolecular autoproteolytic cleavage. J Biol Chem 1992;267:14304-14308.
46. Vey M, Schafer W, Berghofer S, Klenk HD, Garten W. Maturation of the trans-Golgi network protease furin: Compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J Cell Biol 1994;127:1829-1842.
47. Creemers JW, Vey M, Schafer W, Ayoubi TA, Roebroek AJ, Klenk HD, Garten W, Van de Ven WJ. Endoproteolytic cleavage of its propeptide is a prerequisite for efficient transport of furin out of the endoplasmic reticulum. J Biol Chem 1995;270:2695-2702.
48. Molloy SS, Thomas L, VanSlyke JK, Stenberg PE, Thomas G. Intracellular trafficking and activation of the furin proprotein convertase: Localization to the TGN and recycling from the cell surface. EMBO J 1994;13:18-33.
49. Anderson ED, VanSlyke JK, Thulin CD, Jean F, Thomas G. Activation of the furin endoprotease is a multiple-step process: Requirements for acidification and internal propeptide cleavage. EMBO J 1997;16:1508-1518.
50. Zhong M, Munzer JS, Basak A, Benjannet S, Mowla SJ, Decroly E, Chretien M, Seidah NG. The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J Biol Chem 1999;274:33913-33920.
51. Boudreault A, Gauthier D, Lazure C. Proprotein convertase PC1/3-related peptides are potent slow tight-binding inhibitors of murine PC1/3 and Hfurin. J Biol Chem 1998;273:31574-31580.
52. Lazure C, Gauthier D, Jean F, Boudreault A, Seidah NG, Bennett HP, Hendy GN. In vitro cleavage of internally quenched fluorogenic human proparathyroid hormone and proparathyroid-related peptide substrates by furin. Generation of a potent inhibitor. J Biol Chem 1998;273:8572-8580.
53. Cameron A, Fortenberry Y, Lindberg I. The SAAS granin exhibits structural and functional homology to 7B2 and contains a highly potent hexapeptide inhibitor of PC1. FEBS Lett 2000;473:135-138.
54. Basak A, Koch P, Dupelle M, Fricker LD, Devi LA, Chretien M, Seidah NG. Inhibitory specificity and potency of proSAAS-derived peptides toward proprotein convertase 1. J Biol Chem 2001;276:32720-32728.
55. Mbikay M, Seidah NG, Chretien M. Neuroendocrine secretory protein 7 B2: Structure, expression and functions. Biochem J 2001;357:329-342.
56. Nour N, Basak A, Chretien M, Seidah NG. Structure-function analysis of the prosegment of the proprotein convertase PC5A. J Biol Chem 2003;278:2886-2895.
57. Lopez de Cicco R, Bassi DE, Zucker S, Seidah NG, Klein-Szanto AJ. Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res 2005;65:4162-4171.
58. Angliker H, Wikstrom P, Shaw E, Brenner C, Fuller RS. The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J 1993;293:75-81.
59. Angliker H. Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J Med Chem 1995;38:4014-4018.
60. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003;162:439-447.
61. Jiao GS, Cregar L, Wang J, Millis SZ, Tang C, O'Malley S, Johnson AT, Sareth S, Larson J, Thomas G. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci U S A 2006;103:19707-19712.